1. Newsroom
  2. Healthcare IT: A shift with no turning back
Menu
Analisi 02.02.2021

Healthcare IT: A shift with no turning back

Healthcare IT: A shift with no turning back

Although technology in the healthcare industry is still in its infancy, its future will be one of improved health outcomes, increased efficiency, more precise clinical interventions and, ultimately, reduced healthcare expenditure for governments and patients alike.


The COVID-19 outbreak has accelerated the digital transformation of the enormous US healthcare market, which is projected to swell in value to USD 5.7 trillion by 2026. The main driver of technology adoption within the sector remains its ability to reduce costs and improve patient outcomes.

Key messages

  • The pandemic has accelerated the digital transformation of the enormous US healthcare market which is projected to swell in value to USD 5.7 trillion by 2026.
  • The IT sector is responding to healthcare issues, providing savings and improving patient outcomes.
  • The healthcare IT sector will grow massively over the next decade and now is the time to enter this promising investment space.

Worldwide_Healthcare_Expenditure.jpg

Source: Bloomberg Finance LP

At the crossroads of two innovative industries 

Healthcare information technology (HCIT) is at the crossroads of two innovative industries: healthcare & IT. HCIT includes any type of technology used to exchange health-related information across computerised systems between patients, physicians, hospitals, governments, providers, insurers and other stakeholders. 

Fact 1: The US healthcare sector is costly and inefficient 

The US healthcare sector is cost-inefficient as three factors come into play: 

  • Prescriber (physician)/provider (hospital): decides treatment but does not consume or pay
  • Consumer (patient): consumes but does not decide/pay
  • Payer (insurer): pays but does not decide or consume 

US healthcare spending is the highest ratio in the world at nearly 20% of GDP (~USD 3.5 trillion), compared with just 10% in the EU. However, this does not translate into better life expectancy, with close to 50% of Americans living with a chronic condition. We estimate that a third of healthcare spending in the US is wasteful (close to USD 1 trillion). The most significant driving force behind HCIT adoption is decreasing costs and/or optimising current healthcare spending as the global population ages, new diseases appear, and emerging market demand increases further.

Global_Virtual_Care_Market.jpg

Source: Global Market Insight / CAGR estimates

Fact 2: The IT sector is responding to healthcare pain points

  • More convenience: the use of telemedicine is more convenient for patients. In the US, you can get an appointment to see a general practitioner in 10 minutes, compared with an in-person average of ~25 days. 
  • More efficiency: technology, bioinformatics and algorithms allow a human genome to be sequenced in just few hours at a low cost. 
  • Better patient outcomes: tracking blood sugar and insulin levels in real-time through a connected device prevents complications for diabetic patients (hypo/hyperglycaemia). 
  • Less expensive healthcare solutions: thanks to more efficient solutions and better patient outcomes (such as fewer hospitalisations), technology allows for healthcare savings. 

Four promising blocks where HCIT is playing a major role 

HCIT is not a sector by itself and there are many different business models. HCIT companies are often less well-known and/or privately held, and require thorough bottom-up research. Technology is now present across the healthcare sector’s entire value chain. We have identified four blocks which offer attractive characteristics, such as disruptive innovation, strong growth prospects, and a large and underpenetrated market:

  • Virtual care/telemedicine: regulatory hurdles have been removed thanks to the pandemic, which has caused a +300/400% surge in telemedicine use.
  • Informed consumer: out-of-pocket payments by patients are on the rise. There is demand for more transparency and cost efficiency (consumerisation of healthcare).
  • Connected devices: new technologies allow new, accurate and more convenient medical devices, making real-time home care/monitoring possible.
  • Research, diagnosis and monitoring: powerful tools and tests are now available thanks to breakthroughs and technological innovations. 
Advisory Services

Note: The products or services mentioned are provided as general information only and are not intended to provide investment or other advice. Not all products or services described are available in all jurisdictions. Past performance is not a guarantee of future results. For the full disclaimer, please refer to Legal Aspects.


Corby_Pierre_150x150.jpg
Pierre Corby
Healthcare Equity Analyst
Go to his Linkedin profile.

Nicolas_Laroche_150x150.jpg
Nicolas Laroche
Global Head of Advisory Investment
Go to his Linkedin profile.

Analisi

Gestione discrezionale – le redini sono in mano vostra

Ogni cliente ha aspirazioni e obiettivi unici, così come è unico il nostro approccio alla gestione di portafoglio discrezionale.

Leggete di più
Expertise

Swiss & Global Equities

Why Swiss equities now? This market offers equity investors the stability and agility they need to navigate this volatile period. 

Read more
Expertise

European Equities

European equities offer unrivalled opportunities in terms of breadth of sector and market exposure.

Read more

Le news più lette

Analisi 10.02.2021

COVID-19: UBP vi terrà aggiornati

Dalla comparsa del coronavirus, UBP accompagna e sostiene i suoi clienti nel contesto inedito di questa crisi sanitaria mondiale. La Banca vi aggiorna regolarmente sull’adeguamento dei suoi piani alle regole precauzionali fissate dalle autorità e condivide con voi le più aggiornate analisi dei suoi esperti sulle conseguenze della pandemia per l’economia mondiale e i mercati finanziari.

Analisi 24.11.2020

Hidden gems in Swiss & European small caps

Small and mid caps have traditionally recorded higher growth rates and investment returns over the long term than large caps: it is easier to generate a dynamic growth rate from a smaller base. Swiss and European small and medium-sized capitalisations – so-called ‘SMID caps’ – also tend to provide investors with ‘pure play’ exposure to major secular growth trends.

Analisi 17.12.2020

UBP Investment Outlook 2021

Il mondo nuovo

Altro da leggere

Analisi 03.03.2021

Investing amidst a tantrum in US Bond Markets

US 10-year Treasury yields have risen 110 bps from their July, 2020 lows and 60 bps alone in 2021. Using previous bond market ‘tantrums’ going back to 2008 as a reference, a rise to as much as 1.7-2.5% may still lie ahead should the turmoil resume.

Analisi 25.02.2021

UBP’s small- and mid-cap capabilities

SMID-cap equities are poised to mean revert and outperform over the next three to five years. The best time to allocate to SMID caps is when earnings are “depressed”, i.e. now.

Analisi 24.02.2021

The return of leisure & entertainment

The pandemic has not only caused economic chaos around the world, but it has also had a deep impact on people’s lifestyles.